Saptalis Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SAPTALIS PHARMS, and when can generic versions of SAPTALIS PHARMS drugs launch?
SAPTALIS PHARMS has six approved drugs.
There is one US patent protecting SAPTALIS PHARMS drugs.
There are five patent family members on SAPTALIS PHARMS drugs in five countries and sixty-two supplementary protection certificates in fourteen countries.
Drugs and US Patents for Saptalis Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Saptalis Pharms | GLYCOPYRROLATE | glycopyrrolate | SOLUTION;ORAL | 216297-001 | Oct 7, 2024 | AA | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Saptalis Pharms | METFORMIN HYDROCHLORIDE | metformin hydrochloride | SOLUTION;ORAL | 211309-001 | Mar 3, 2020 | AB | RX | No | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
Saptalis Pharms | LIKMEZ | metronidazole | SUSPENSION;ORAL | 216755-001 | Sep 22, 2023 | RX | Yes | Yes | 11,541,035 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
Saptalis Pharms | VOSOL HC | acetic acid, glacial; hydrocortisone | SOLUTION/DROPS;OTIC | 012770-001 | Approved Prior to Jan 1, 1982 | AT | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
Saptalis Pharms | CLOBETASOL PROPIONATE | clobetasol propionate | SOLUTION;TOPICAL | 211494-001 | Oct 2, 2019 | AT | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
Saptalis Pharms | CYCLOSPORINE | cyclosporine | EMULSION;OPHTHALMIC | 211943-001 | Jul 5, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Saptalis Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
European Patent Office | 3768321 | ⤷ Subscribe |
World Intellectual Property Organization (WIPO) | 2019140516 | ⤷ Subscribe |
Canada | 3087789 | ⤷ Subscribe |
Mexico | 2020007494 | ⤷ Subscribe |
Brazil | 112020014376 | ⤷ Subscribe |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Saptalis Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1412357 | DO 77; 5006-2008 | Slovakia | ⤷ Subscribe | PRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716 |
1261586 | 12C0028 | France | ⤷ Subscribe | PRODUCT NAME: ASSOCIATION COMPRENANT LA SAXAGLIPTINE OU UN DE SES SELS ET LA METFORMINE OU UN DE SES SELS, Y COMPRIS L'ASSOCIATION CHLORHYDRATE DE SAXAGLIPTINE ET CHLORHYDRATE DE METFORMINE; REGISTRATION NO/DATE: EU/1/11/731/001 20111124 |
2498758 | 2090013-0 | Sweden | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF METFORMIN HYDROCHLORIDE, SAXAGLIPTIN OR A PHARMACEUTICALLY ACCEPABLE SALT THEREOF, AND DAPAGLIFLOZIN OR PH ARMACEUTICALLY ACCEPTABLE SOLVATE THEREOF; REG. NO/DATE: EU/1/19/1401 20191113 |
2435024 | 2021C/518 | Belgium | ⤷ Subscribe | PRODUCT NAME: UNE COMBINAISON DE FORMOTEROL (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES), GLYCOPYRROLATE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES) ET BUDESONIDE (Y COMPRIS TOUS SES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES); AUTHORISATION NUMBER AND DATE: EU/1/20/1498 20201210 |
1586316 | C 2011 004 | Romania | ⤷ Subscribe | PRODUCT NAME: BROMFENAC, SARURILE SI HIDRATII SAI ACCEPTABILI FARMACEUTICACID 2-[2-AMINO-3-(4-BROMOBENZOIL)FENILACETIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/692/001; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/11/692/001; DATE OF FIRST AUTHORISATION IN EEA: 20110518 |
2498758 | 301040 | Netherlands | ⤷ Subscribe | PRODUCT NAME: METFORMINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; SAXAGLIPTINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; DAPAGLIFLOZINE OF EEN FARMACEUTISCH AANVAARDBAAR SOLVAAT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1401 20191113 |
1506211 | PA2014026 | Lithuania | ⤷ Subscribe | PRODUCT NAME: DAPAGLIFOZINUM + METFORMINUM; REGISTRATION NO/DATE: EU/1/13/900 20140116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.